Clascoterone full results in July 5/14/2026
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Excited! Just got prescribed Clascoterone 5%
The user is excited about starting Clascoterone 5% for hair loss, a DHT blocker, and expects better results when combined with Minoxidil. The prescription costs $199 for 30 ml or $353 for 60 ml, and the user plans to cover the cost by driving for Uber.
community Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
community 6 years on Fin. This shit is goated.
Finasteride is effective for maintaining hair and stopping hair loss, with many users experiencing long-term success and minimal side effects. Some users consider switching to Dutasteride or adding Minoxidil for additional regrowth.
community Whatever happened to Clascoterone? (breezula for hair) (sold as Winlevi for acne available since 2021)
Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.
community Don't be inconsistent with Minoxidil, you will lose progress fast. My new plan for future.
Inconsistent minoxidil use led to hair loss, prompting a plan to resume consistent application with derma stamping, red light therapy, and DHT blockers like clascoterone or RU58841. The user avoids finasteride and dutasteride due to past side effects.
Related Research
6 / 6 resultsresearch Clascoterone: First Approval
This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.
research Use of topical clascoterone for the treatment of hidradenitis suppurativa
This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
research Clascoterone as a novel treatment for androgenetic alopecia
This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.
research Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.
research Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.